Venous thromboembolism in cancer clinical trials: Recommendation for standardized reporting and analysis

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 12, 2012, Pages 2599-2601

  Carrier, M ^a   Khorana, A A ^b   Zwicker, J I ^c   Lyman, G H ^d   Le Gal, G ^e   Lee, A Y Y ^f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e Universite de Brest   (France)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; CANCER PATIENT; CATHETER THROMBOSIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; HUMAN; IMMUNOMODULATION; INCIDENCE; LUNG EMBOLISM; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; QUALITY OF LIFE; RISK FACTOR; SUPERFICIAL THROMBOPHLEBITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84871079890     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12028     Document Type: Article

References (14)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-4.
2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
3. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; Issue 3: Art. No.: CD003407.
4. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-85.
5. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-23.
6. Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9: 653-63.
7. Mandalà M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, Mosconi S, Corsi D, Rulli E, Frontini L, Cortesi E, Zaniboni A, Aglietta M, Labianca R. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45: 65-73.
8. Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364: 861-9.
9. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG, Makdissi R, Guyatt GACoCP. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(Suppl. 2): e351S-418S.
10. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-9.
11. van Belle A, Buller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, Kramer MH, Kruip MJ, Kwakkel-van Erp JM, Leebeek FW, Nijkeuter M, Prins MH, Sohne M, Tick LW. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295: 172-9.
12. Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of kaplan and meier. J Thromb Haemost 2012; 10: 1449-51.
13. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-65.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.